Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Matilde Bacchion
Based on 3 articles published since 2010
(Why 3 articles?)

Between 2010 and 2020, M. Bacchion wrote the following 3 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Pancreatic cystic tumours: when to resect, when to observe. 2010

Salvia, R / Crippa, S / Partelli, S / Malleo, G / Marcheggiani, G / Bacchion, M / Butturini, G / Bassi, C. ·Department of Surgery, Chirurgia Generale B, Policlinico "GB Rossi", University of Verona, Verona, Italy. ·Eur Rev Med Pharmacol Sci · Pubmed #20496554.

ABSTRACT: BACKGROUND AND OBJECTIVES: In recent years there has been an increase in the diagnosis of cystic tumors of the pancreas. In this setting, difficult diagnostic problems and different therapeutic management can be proposed. MATERIAL AND METHODS: A review of the literature and authors experience were undertaken. RESULTS: Cystic tumors of the pancreas include different neoplasms with a different biological behaviour. While most serous cystadenomas (SCAs) can be managed nonoperatively, patients with mucinous cystic neoplasms (MCNs), solid pseudopapillary tumors (SPTs), main-duct intraductal papillary mucinous neoplasms (IPMNs) should undergo surgical resection. Branch-duct IPMNs can be observed with radiological and clinical follow-up when asymptomatic, < 3 cm in size and without radiologic features of malignancy (i.e. nodules). CONCLUSIONS: Cystic tumors of the pancreas are common. Differential diagnosis among the different tumor-types is of paramount importance for appropriate management. Nonoperative management seems appropriate for most SCAs and for well-selected branch-duct IPMNs.

2 Clinical Trial Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. 2015

Paiella, Salvatore / Butturini, Giovanni / Frigerio, Isabella / Salvia, Roberto / Armatura, Giulia / Bacchion, Matilde / Fontana, Martina / D'Onofrio, Mirko / Martone, Enrico / Bassi, Claudio. ·Unit of Pancreatic and General Surgery, The Pancreas Institute, G.B. Rossi Hospital, University of Verona Hospital Trust, Verona, Italy. ·Dig Surg · Pubmed #25765775.

ABSTRACT: PURPOSE: To evaluate the safety of the NanoKnife Low Energy Direct Current (LEDC) System (Irreversible Electroporation, IRE) in order to treat patients with unresectable pancreatic adenocarcinoma. METHODS: Prospective, nonrandomized, single-center clinical evaluation of ten patients with a cytohystological diagnosis of unresectable locally advanced pancreatic cancer (LAPC) that was no further responsive to standard treatments. The primary outcome was the rate of procedure-related abdominal complications. The secondary endpoints included the evaluation of the short-term efficacy of IRE through the evaluation of tumor reduction at imaging and biological tumor response as shown by CA 19-9, clinical assessments and patient quality of life. RESULTS: Ten patients (5 males, 5 females) were enrolled, with a median age of 66 and median tumor size of 30 mm. All patients were treated successfully with a median procedure time of 79.5 min. Two procedure-related complications were described in one patient (10%): a pancreatic abscess with a pancreoduodenal fistula. Three patients had early progression of disease: one patient developed pulmonary metastases 30 days post-IRE and two patients had liver metastases 60 days after the procedure. We registered an overall survival of 7.5 months (range: 2.9-15.9). CONCLUSIONS: IRE is a safe procedure in patients with LAPC and may represent a new technological option in the treatment and multimodality management of this disease.

3 Article Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. 2017

Giardino, Alessandro / Innamorati, Giulio / Ugel, Stefano / Perbellini, Omar / Girelli, Roberto / Frigerio, Isabella / Regi, Paolo / Scopelliti, Filippo / Butturini, Giovanni / Paiella, Salvatore / Bacchion, Matilde / Bassi, Claudio. ·Hepato-Biliary and Pancreatic Unit, Ospedale Dott. Pederzoli, Peschiera del Garda, VR, Italy. Electronic address: giardinochir@gmail.com. · LURM - Research Laboratory, University of Verona, Italy. · Immunology, University of Verona, Italy. · Ematology Research Laboratory, Vicenza Hospital, VI, Italy. · Hepato-Biliary and Pancreatic Unit, Ospedale Dott. Pederzoli, Peschiera del Garda, VR, Italy. · Pancreas Institute, University of Verona, Italy. · General Surgery Department, Pederzoli Hospital, Peschiera del Garda, VR, Italy. ·Pancreatology · Pubmed #29037917.

ABSTRACT: OBJECTIVE/BACKGROUND: RFA of pancreatic cancer has been demonstrated to be feasible and safe with a positive impact on survival. The aim was to investigate whether an immune reaction is activated after locally advanced pancreatic cancer (LAPC) ablation. METHODS: Peripheral Blood samples were obtained preoperatively and on post-operative days 3-30. Evaluated parameters were: cells [CD4 RESULTS: Ten patients were enrolled. CD4 CONCLUSIONS: This study provides the first evidence of RFA-based immunomodulation in LAPC. We observed a general activation of adaptive response along with a decrease of immunosuppression. Furthermore, most cells showed prolonged activation some weeks after the procedure, suggesting true immunomodulation rather than a normal inflammatory response.